Epigenetic signature at FOXP3 distal enhancer affects regulatory T cell development in Kabuki syndrome

This study identifies Kabuki syndrome as a novel Tregopathy caused by KMT2D loss-of-function, which disrupts the epigenetic signature at the FOXP3 distal enhancer to impair regulatory T cell development and offers in vitro demethylation as a potential therapeutic strategy.

The Gist

The Big Picture: Kabuki Syndrome and the "Immune Security Guard"

Imagine your body is a massive, bustling city. To keep this city safe, you have a special police force called Regulatory T cells (Tregs). Their job is to act as "security guards" or "peacekeepers." They stop the immune system from attacking your own healthy cells (which causes autoimmune diseases) and keep the peace when there are infections.

Kabuki Syndrome is a genetic condition people are born with. Think of it like a construction error in the blueprint of the city. Specifically, the blueprint for a foreman named KMT2D is broken. This foreman is supposed to manage the construction of the peacekeepers (Tregs).

This new study discovered that because the KMT2D foreman is broken, the city ends up with too few peacekeepers. This explains why people with Kabuki syndrome often suffer from both infections (because they don't have enough guards) and autoimmune problems (because the few guards they have aren't working right).

---

The Mystery: Why Are the Guards Missing?

Scientists knew people with Kabuki syndrome had low numbers of these peacekeepers, but they didn't know why. Was the factory broken? Was the blueprint missing?

The researchers found the answer lies in epigenetics.

The Analogy: The Library and the Book

Imagine the gene that makes the peacekeeper (called FOXP3) is a very important instruction book in a library.

• Healthy People: In a healthy library, the book is open, the lights are on, and the librarian (KMT2D) has placed a "Do Not Disturb" sign on the shelf to keep it clean and ready to be read. The instructions are clear, and the peacekeepers are built.
• Kabuki Patients: In these patients, the librarian is missing. Because the librarian isn't there, someone else (a "cleaning crew" called DNA methyltransferases) comes in and slams the book shut, covers it in thick dust, and locks it in a cage. This is called methylation.

Even though the book (the gene) is physically there, it is locked and dusty. The factory can't read the instructions, so it stops making the peacekeepers.

The Smoking Gun: The "Methylated Core"

The researchers used a high-tech microscope (sequencing) to look at the "dust" on the book. They found a very specific pattern of dust.

• The Metaphor: Imagine the instruction book has a specific chapter (the distal enhancer) that tells the factory when to start working.
• The Discovery: In healthy people, this chapter is clean. In Kabuki patients, this specific chapter is covered in a unique, heavy layer of dust that the researchers call a "Methylated Core."

This specific pattern of dust acts like a permanent "OFF" switch. It stops the gene from turning on, leading to a shortage of peacekeepers.

The Twist: The Factory Gets Confused

When the peacekeepers aren't made, the factory doesn't just stop; it gets confused and starts building the wrong things.

• The Analogy: Because the "Peacekeeper" instructions are locked, the factory switches to building "Aggressive Soldiers" (specifically Th2 cells).
• The Result: Instead of keeping the peace, the body starts overreacting to harmless things (like pollen or food), leading to allergies and autoimmune attacks. This explains why Kabuki patients often have severe allergies and autoimmune diseases.

The Good News: We Can Unlock the Book!

The most exciting part of this study is that the "OFF" switch isn't permanent. The book isn't torn up; it's just locked.

The researchers tried a treatment in the lab using a chemical called Azacytidine.

• The Metaphor: Think of Azacytidine as a master key or a dust-buster.
• The Experiment: When they used this "key" on the Kabuki cells in the lab, it wiped away the dust and unlocked the cage.
• The Result: The factory suddenly started reading the instructions again! They began making the peacekeepers (FOXP3) and stopped making the aggressive soldiers.

Why This Matters

1. New Diagnosis: This study proves that Kabuki syndrome is a type of "Tregopathy" (a disease caused by broken peacekeepers). Doctors can now look for this specific "dust pattern" to understand a patient's immune problems better.
2. New Hope: Since the problem is a "lock" (epigenetic) and not a "broken part" (genetic mutation), it might be reversible. This opens the door for new drugs that can act as the "master key" to unlock the immune system in Kabuki patients, potentially curing their autoimmune issues and infections.

In short: Kabuki syndrome breaks the foreman (KMT2D), which causes the instruction book for immune peacekeepers to get locked in a cage. This study found the specific lock, and showed that with the right key, we can unlock the cage and restore the immune system's balance.

Technical Summary

1. Problem Statement

Kabuki Syndrome (KS) is a congenital developmental disorder caused by loss-of-function (LoF) pathogenic variants in the lysine methyltransferase KMT2D (KS1) or the lysine demethylase KDM6A (KS2). Patients exhibit a complex immune dysregulation phenotype, ranging from immunodeficiency (recurrent infections, hypogammaglobulinemia) to severe autoimmunity (Evans syndrome, thyroiditis, vitiligo).

While the genetic cause is known, the molecular mechanism linking KMT2D deficiency to the specific immune dysregulation remains unclear. Previous studies suggested a link to Common Variable Immunodeficiency (CVID)-like features, but the role of Regulatory T cells (Tregs)—the master regulators of immune tolerance—had not been fully elucidated. The authors hypothesized that the immune defects in KS are driven by an impaired generation of CD4+FOXP3+ Tregs due to epigenetic dysregulation of the FOXP3 gene.

2. Methodology

The study employed a multi-faceted approach combining clinical immunology, molecular biology, and advanced epigenetic sequencing:

• Cohort: 12 pediatric patients with confirmed KMT2D LoF mutations (KS1) and 20 age/sex-matched healthy subjects (Hs).
• Immunophenotyping: Flow cytometry analysis of peripheral blood mononuclear cells (PBMCs) to quantify Treg subsets (CD4+FOXP3+, CD4+FOXP3E2+), Tconv cells, and expression of lineage markers (CTLA-4, CD45RA, CCR7, PD-1, CD71, CD31).
• In Vitro Differentiation: Induction of inducible Tregs (iTregs) from sorted conventional T cells (Tconvs) using anti-CD3/anti-CD28 stimulation.
• Functional Assays:
  • Suppressive Assay: Co-culture of Tregs with Tconvs to measure suppression of proliferation.
  • Western Blot & qPCR: Analysis of protein and mRNA levels of FOXP3 variants, signaling molecules (STAT5, STAT3, EZH2, p-S6), and lineage drivers (GATA3, Blimp-1).
  • KMT2D Silencing: siRNA knockdown of KMT2D in healthy Tconvs to mimic the KS phenotype.
• Epigenetic Analysis (Key Innovation):
  • Targeted Deep Bisulfite Sequencing: Analyzed four regulatory regions of FOXP3: Distal enhancer (CNS0, Regions I & II), Proximal promoter (Region III), and CNS2 (Region IV).
  • MethCore Analysis: Used the MethCoresProfiler algorithm to identify specific "Methylated Core" (MethCore) signatures—families of epialleles sharing a specific methylation pattern—rather than relying solely on average methylation levels.
• Therapeutic Rescue: Treatment of KS-Tconvs with 5-azacytidine (aza), a DNA methyltransferase inhibitor, during iTreg induction to test if demethylation could restore FOXP3 expression.

3. Key Contributions

• Identification of KS as a Novel Tregopathy: The study classifies Kabuki Syndrome as a primary immunodeficiency characterized by a quantitative and qualitative defect in Treg development, distinct from IPEX syndrome but sharing overlapping features.
• Discovery of a Specific Epigenetic Signature: The authors identified a unique Methylated Core (Ks-MethCore) at the FOXP3 distal enhancer (CNS0) specific to KS patients. This signature was undetectable by traditional average methylation analysis but revealed a specific structural pattern of CpG methylation.
• Mechanistic Link between KMT2D and DNA Methylation: The study establishes a causal chain: KMT2D LoF $\rightarrow$ loss of H3K4me1 (histone modification) $\rightarrow$ recruitment of de novo DNA methyltransferases (DNMT3A) $\rightarrow$ hypermethylation of the FOXP3 distal enhancer $\rightarrow$ transcriptional silencing of FOXP3.
• Reversibility: Demonstration that the epigenetic defect is reversible via pharmacological demethylation, offering a potential therapeutic avenue.

4. Key Results

A. Immunological Phenotype

• Reduced Treg Numbers: KS patients showed a significant reduction in absolute numbers and percentages of CD4+FOXP3+ Tregs and the more suppressive CD4+FOXP3E2+ subset compared to healthy controls.
• Altered Phenotype: KS Tregs exhibited lower expression of naive/memory markers (CD45RA, CCR7, CD31) and higher expression of activation markers (PD-1, CD71), suggesting an expansion of the effector memory compartment and reduced thymic emigration.
• Functional Defect: While the suppressive function was largely intact in the tested cohort (likely due to assay saturation at 1:1 ratios), the quantitative defect was confirmed by low frequencies of TSDR-demethylated cells (a marker of stable Tregs).

B. Molecular Mechanism

• FOXP3 Suppression: In vitro induction of iTregs from KS patients resulted in significantly reduced expression of all FOXP3 isoforms (47/44 kDa) and the FOXP3E2 variant.
• Signaling Dysregulation: KS Tconvs showed decreased activation of STAT5/STAT3 (required for FOXP3) and increased expression of EZH2 and p-S6 (mTOR pathway), both of which repress FOXP3.
• Lineage Skewing: The failure to induce FOXP3 led to a compensatory upregulation of GATA3 and Blimp-1, driving differentiation toward the Th2 lineage instead of Tregs. This aligns with the high prevalence of atopy and allergic conditions in KS.
• KMT2D Validation: Silencing KMT2D in healthy Tconvs recapitulated the KS phenotype (reduced FOXP3, increased GATA3), confirming the direct role of the enzyme.

C. Epigenetic Findings

• Specific MethCore: While average methylation levels at FOXP3 regions were similar between groups, deep sequencing revealed a distinct Ks-MethCore at the distal enhancer (Region I). This core consists of 18 specific CpGs that are co-methylated in KS patients but not in healthy controls.
• Correlation with Expression: The frequency of the Ks-MethCore correlated with reduced FOXP3 transcription.
• Rescue: Treatment with 5-azacytidine successfully demethylated the locus, restored FOXP3 expression (particularly the E2 variant), and rescued Treg induction in KS cells.

5. Significance and Conclusion

This paper provides a critical molecular explanation for the immune dysregulation in Kabuki Syndrome. It moves beyond the observation of "low Tregs" to define the epigenetic mechanism (specific DNA methylation at the FOXP3 distal enhancer) caused by KMT2D loss.

• Clinical Implication: The identification of KS as a Tregopathy suggests that monitoring Treg numbers and function is crucial for managing KS patients.
• Therapeutic Potential: The finding that the defect is reversible with DNA methyltransferase inhibitors (like azacytidine) opens a new window for targeted therapies to restore immune homeostasis in KS, potentially preventing or treating severe autoimmunity.
• Broader Impact: The study highlights how histone methyltransferase defects can indirectly drive DNA methylation changes, a mechanism that may be relevant in other epigenetic disorders.

In summary, the authors demonstrate that KMT2D deficiency creates a specific epigenetic barrier at the FOXP3 enhancer, preventing Treg development and skewing T cells toward a Th2 phenotype, thereby defining Kabuki Syndrome as a novel, reversible Tregopathy.